Disease modification in OA — will we ever get there?
Forskningsoutput: Tidskriftsbidrag › Debate/Note/Editorial
No drugs are currently approved that change the natural course of osteoarthritis (OA) and translate to long-term, clinically relevant benefits. Two-stage clinical trial designs for OA have now received FDA approval, but remaining challenges lie in defining suitable study populations, surrogate outcomes and pivotal long-term, clinically relevant trial endpoints.
|Enheter & grupper|
Ämnesklassifikation (UKÄ) – OBLIGATORISK